ଫୁସଫୁସ କ୍ୟାନ୍ସର (ନନ୍-ସ୍ମଲ୍ ସେଲ୍)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
କେଉଁଠିକୁ ଯିବେ
ଏହି ଟ୍ରାଏଲ୍ ପାଇଁ ଭାରତରେ 12 ଟି ହସ୍ପିଟାଲ୍ ରୋଗୀଙ୍କୁ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
ସ୍ପୋନ୍ସର: ଏଲି ଲିଲି ଆଣ୍ଡ କମ୍ପାନୀ
କ୍ଲିନିକାଲ୍ ଟ୍ରାଏଲ୍ସ.gov ରେ NCT06890598
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 7 ଅକ୍ଟୋବର 2026 · ଆମ ଦ୍ୱାରା 20 ଅକ୍ଟୋବର 2026 ରେ ପଢାଯାଇଛି